Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CHKA | P35790 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26378176 | 0.95 | CHKA (0.68) | LMNAMC4RALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL17465252 | 0.93 | CHKA (0.71) | LMNAMC4RALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL19852589 | 0.86 | LMNA (0.59) | LMNAMC4RALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21378560 | 0.86 | LMNA (0.64) | LMNAMC4RALDH1A1CHKACA2 | |
| SCHEMBL19778598 | 0.86 | LMNA (0.64) | LMNAMC4RALDH1A1CHKACA2 | |
| SCHEMBL15960142 | 0.86 | LMNA (0.64) | LMNAMC4RALDH1A1CHKACA2 | |
| SCHEMBL22794049 | 0.86 | ALDH1A1 (0.57) | LMNAALDH1A1HTTSMN1; SMN2FAAH | |
| SCHEMBL14923999 | 0.85 | ALDH1A1 (0.65) | LMNAALDH1A1HTTSMN1; SMN2HTR6 | |
| SCHEMBL4547890 | 0.85 | HRH3 (0.65) | ALDH1A1HTTSMN1; SMN2NCF1HRH3 | |
| SCHEMBL4547912 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2CHKACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11584805-B2 | Oligosaccharide compositions and methods for producing thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220400728-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS FOOD INGREDIENTS AND METHODS OF PRODUCING THEREOF | CADENA BIO INC (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2022249764-A1 | RUBBER COMPOSITION FOR TIRE, TREAD RUBBER, AND TIRE | 株式会社ブリヂストン | 2022-12-01 | — | — | WO | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3481830-B1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007112491-A1 | MICROREACTOR | THE UNIVERSITY OF TASMANIA (AU) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | LMNA 2409/4885MC4R 422/4885ALDH1A1 684/4885 |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | LMNA 97/4885MC4R 3640/4885ALDH1A1 3017/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | LMNA 4580/4885MC4R 598/4885ALDH1A1 2375/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | LMNA 2477/4885MC4R 1266/4885ALDH1A1 1432/4885 |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | LMNA 4064/4885MC4R 1572/4885ALDH1A1 1744/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | LMNA 4817/4885MC4R 1157/4885ALDH1A1 3235/4885 |
| US-11584805-B2 | Oligosaccharide compositions and methods for producing thereof | OSTC, FUT5, FUT6 | LMNA 3774/4885MC4R 3058/4885ALDH1A1 2641/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | LMNA 4713/4885MC4R 2112/4885ALDH1A1 4790/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | LMNA 4833/4885MC4R 1232/4885ALDH1A1 2446/4885 |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | LMNA 3462/4885MC4R 1280/4885ALDH1A1 3807/4885 |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | ACE, SARS1, ACE2 | LMNA 1282/4885MC4R 4811/4885ALDH1A1 1957/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | LMNA 4580/4885MC4R 598/4885ALDH1A1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.